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Vivienne J Zhu1,2*, Anne Belsito1, Wanzhu Tu1,2 and J Marc Overhage2,3Abstract
Background: Observational data are increasingly being used for pharmacoepidemiological, health services and
clinical effectiveness research. Since pharmacies first introduced low-cost prescription programs (LCPP), researchers
have worried that data about the medications provided through these programs might not be available in
observational data derived from administrative sources, such as payer claims or pharmacy benefit management
(PBM) company transactions.
Method: We used data from the Indiana Network for Patient Care to estimate the proportion of patients with type
2 diabetes to whom an oral hypoglycemic agent was dispensed. Based on these estimates, we compared the
proportions of patients who received medications from chains that do and do not offer an LCPP, the proportion
trend over time based on claims data from a single payer, and to proportions estimated from the Medical
Expenditure Panel Survey (MEPS).
Results: We found that the proportion of patients with type 2 diabetes who received oral hypoglycemic
medications did not vary based on whether the chain that dispensed the drug offered an LCPP or over time.
Additionally, the rates were comparable to those estimated from MEPS.
Conclusion: Researchers can be reassured that data for medications available through LCPPs continue to be
available through administrative data sources.
Keywords: Low-cost prescription program, Oral antihyperglycemic agents, Pharmacy benefit manager, Claims dataBackground
When pharmacies dispense a medication for a patient
who has a drug benefit, they typically submit an elec-
tronic transaction to a pharmacy benefit management
(PBM) adjudication system as a method to confirm eligi-
bility and to request payment. The PBM returns a trans-
action which contains status data about the adjudication
and later transfers the transaction data to the payer who
contracted with them for services.
In 2006, pharmacies introduced low-cost prescription
programs (LCPP) offering selected generic medications
that included those for common diseases, such as dia-
betes, hypertension, and asthma, for $5 or less for a 30-* Correspondence: jiazhu@iupui.edu
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reproduction in any medium, provided the orday supply (they sometimes offer a 90-day supply for
$10 to $15) [1]. Researchers and others who rely on
claims data became concerned that, since the dispensing
pharmacy would be unlikely to receive additional reim-
bursement from the payer and there may be direct and
indirect costs associated with submitting the claim, the
pharmacy might often not submit a claim when the pa-
tient purchased one of these low cost prescriptions using
cash. [2,3] Failing to submit claims for these drugs, many
of which are commonly used, would diminish the value
of administrative data sources for research [4]. Even if
the drug in question was not the primary focus of a
study, important confounding or comorbidity data could
be lost.
In order to determine whether LCPPs have an effect
on the availability of low-cost medication dispensing
data through claims, we analyzed data from a large. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion of patients receiving each oral hypoglycemic medi-
cation available through LCPPs at pharmacy chains with
and without LCPPs. We also compared the proportion
of patients who had at least one prescription for an oral
hypoglycemic medication before and after pharmacies
implemented LCPPs. Our hypothesis was that, if patients
pay cash for medications available through LCPPs, the
proportion of patients appearing to use these medica-
tions would appear lower for chains with LCPP com-
pared to chains without these programs. Similarly, we
would expect the proportion of patients receiving each
of these medications to appear to fall after the pharmacy
chains implemented LCPPs.
Methods
This study was approved by the Institutional Review
Board of Indiana University. We chose to base our
evaluation on patients with type 2 diabetes, a common
disease that requires treatment with medications chron-
ically. We chose to study patients with a specific condi-
tion in order to allow us to estimate usage rates
(proportion of patients who received a prescription for a
drug) which we could compare across chains with and
without LCPPs from 2008 to 2010, before and after the
LCPP implementation from 2002 to 2010, as well as
with estimates based on the most recent Medical Ex-
penditure Panel Survey, a nationally representative sur-
vey of medical care use and expenditures.
Indiana network for patient care
The Indiana Network for Patient Care (INPC) is an op-
erational regional health information exchange, which
collects and transfers healthcare information electronic-
ally across organizations within a region, community or
hospital system [5]. The INPC services more than 75
participating hospitals as well as laboratories, radiology
centers, public health departments, long-term care facil-
ities, payers, some pharmacies, and PBMs, and the INPC
has served Indianapolis for more than 15 years [1,6]. In
particular the INPC includes pharmacy claims data from
the largest public and private payors as well as medica-
tion history data from PBMs obtained via the Sure-
scripts network. Surescripts is the country’s largest
electronic prescribing network providing electronic ac-
cess to prescription information. It connects all of the
nation’s major chain pharmacies, many of the nation’s
leading payers, and over 10,000 independent pharmacies
nationwide. The medication data usually include patient
identifying data, such as name, gender, ethnicity, and ad-
dress; drug data, including a coded identifier, whether
the drug dispensed was branded, and the number of
days’ supply dispensed; and dispensing pharmacy infor-
mation, including the National Council for PrescriptionDrug Programs (NCPDP) pharmacy code. We map the
coded drug identifiers (almost always National Drug
Codes but sometimes pharmacy specific codes) indir-
ectly to the RxNORM codes (a standardized nomencla-
ture for clinical drugs and drug delivery devices
developed and maintained in the National Library of
Medicine), which allowed us to aggregate drugs at the
level of active ingredients. We selected commonly used
antidiabetic medications (First DataBank Standard
Therapeutic Class Code: 71), including selected oral
hypoglycemic agents (OHA) therapeutic classes: sulfony-
lurea, biguanides, thiazolidinediones, α-glucosidase inhi-
bitors, meglitinides, dipeptidyl-peptidase-4 inhibitors,
and antidiabetic combinations.
Pharmacy data
Using the NCPCP pharmacy database, we aggregated
dispensing locations into chains by store name. We
defined an LCPP as a program that offered 30-day sup-
plies of medications for $5 or less and which did not
have obvious barriers to participation, such as annual
membership fees or difficult enrollment processes. In
addition to reviewing the grey and published literature
[4,7], we reviewed both the current and past versions of
the websites for each of the 14 chains in our database to
determine which offered an LCPP and which antidia-
betic medications were currently included in the pro-
gram. [7,8] Using these data, we identified five major
chains which implement LCPP and provide generic anti-
diabetic medication (glimepiride, glipizide, glyburide,and
metformin). While the chains implemented their LCPPs
at slightly different times, they essentially started in the
4th quarter of 2006, and most were implemented by the
4th quarter of 2007.
Measurements
In order to construct a measure of the rate of medica-
tion use for each category, we identified all patients in
the Indianapolis Metropolitan Statistical Area (MSA)
who had at least one clinical encounter with type 2 dia-
betes (ICD-9-CM codes 250.X0 or 250.X2 as the primary
diagnosis) from 2008 to 2010. We then assigned each
patient who had at least 3 medication dispensing records
(assuming that patients with a chronic disease on
chronic medications would have a minimum of 4 dis-
pensing events over the course of 1 year, even if they
received 90-day supplies and were only being treated
with 1 drug) to the pharmacy chain through which they
received their prescriptions. We excluded patients who
received prescriptions from more than 1 chain during
the study period from the cohort in order to eliminate
any cross-over effects. Next, we computed the rate at
which each drug was used in each pharmacy chain co-
hort of patients. If a patient had at least 1 dispensing
Figure 1 Patient selection.




Age of dispensing Female White
Chains (Mean±SD)
Chain1† 424 63.9 ± 12.0 50.70% 83.20%
Chain2 489 61.2 ± 13.0 43.90% 87.50%
Chain3 693 66.4 ± 10.4 51.50% 81.70%
Chain4† 727 60.7 ± 13.1 45.20% 91.20%
Zhu et al. BMC Clinical Pharmacology 2012, 12:12 Page 3 of 7
http://www.biomedcentral.com/12/1/12/12/12event for the drug, we included them in the numerator,
while the total number of diabetic patients attributed to
the pharmacy chain was used as the denominator. Using
the same approach, we measured the proportion of
patients using individual OHA longitudinally (2002 to
2010) for a single payer.
In order to obtain comparable independent estimates
of rates of use of these drugs nationally, we extracted
data from the Medical Expenditure Panel Survey (MEPS)
2008 Prescribed Medicines dataset (file: HC-118A). [9]
The MEPS study is a large-scale survey of families and
individuals, their medical providers, and employers
across the United States by the Agency for Healthcare
Research and Quality (http://www.meps.ahrq.gov/meps-
web/). The estimated proportion of diabetes patients
using each OHA drug in the year 2008 was used as a
reference measure. We selected patients who had at
least 1 diagnosis code for diabetes and used the MEPS
weightings to project the proportion of diabetic patients
receiving each active ingredient to the U.S. population.Chain5† 810 53.5 ± 12.3 52.30% 84.20%
Chain6{ 966 57.3 ± 12.6 45.60% 83.60%
Chain7 1,708 60.8 ± 11.0 40.10% 89.60%
Chain8 2,892 60.8 ± 10.2 40.80% 91.80%
Chain9 3,461 64.0 ± 11.0 43.10% 87.80%
Chain10† 3,932 59.1 ± 12.8 51.00% 87.70%
Chain11† 5,623 57.6 ± 12.3 50.80% 82.40%
Chain12 7,971 58.2 ± 12.8 51.70% 75.10%
Chain13 9,882 66.6 ± 10.6 43.10% 85.10%
Chain14† 16,788 59.1 ± 12.9 49.00% 79.00%
MEPS 13.7million 60.7 ± 12.8 44.2% 66.8%
† Chain with a LCPP.
{ Chain with LCPP for Chlorpropamide only.Analysis
Primarily, we compared the rates at which a specific
medication was dispensed to diabetic patients between
chains offering and not offering an LCPP. In the general-
ized linear mixed models (GLMM), the dispensing event
of low-cost medications was the dependent variable, and
the low-cost program was used as the independent vari-
able. Odds ratios (OR) were used to quantify the magni-
tude of associations between these 2 variables. Both
adjusted and unadjusted associations were estimated. Pa-
tient age, gender, race, and pharmacy chain were used as
covariates (fixed effects) for the adjusted analysis.Patients were included in the model as the random
effect.
In order to take account into secular trends, we sec-
ondarily evaluated longitudinal trends of the proportion
of patients using low-cost medication in major chains
with and without LCPP. The interrupted time series ana-
lyses with control group were performed to assess the
immediate changes of proportion of low-cost OHA use
after LCPP implementation and to analyze if any detect-
able change was caused by the LCPP. For this analysis,
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quarterly. Changes of proportion of low-cost OHA use
and changes of the slopes between pre-intervention
period (2002, quarter 1 to 2006, quarter 4) and post-
intervention period (2007, quarter 1 to 2010, quarter 4)
were estimated and compared for chains with LCPP
(intervention) and without LCPP (control).
Results
We identified 48,060 diabetic patients who received at
least 3 prescriptions from one-and-only-one of 14 phar-
macy chains (4,129 individual pharmacies) which cover
more than 95% of INPC patients who had OHA dispens-
ing records (Figure 1). The demographic characteristics
of the patient cohorts were similar across chains
(Table 1). Among a total of 620,648 OHA dispensing
events, 268,473 were dispensed from chains without an
LCPP and 352,175 were dispensed from chains with an
LCPP. Overall, the percentage of dispensing events of
low-cost medications was higher in pharmacy chains
which have low-cost programs: 71.7% vs. 66.1%. AfterFigure 2 Proportion of patients using selected oral hypoglycemic agecontrolling for patient gender, race, and chain, chains
with an LCPP are more likely to dispense an OHA
which is available as a low-cost medication (OR:
1.21,95% CI [1.19,1.22], p< 0.0001). Proportions of
patients for which each OHA was dispensed are similar
for drugs across chains whether they offer an LCPP or
not (Figure 2). In addition, the proportions of diabetic
patients receiving each medication based on projections
from the MEPS data were similar to those in our Indian-
apolis cohorts (Table 2).
From the longitudinal (2002–2010) dataset, a total of
18,775 patients were identified (14,220 for LCPP with
154,525 low-cost OHA dispensing events, and 4,555 for
non-LCPP with 74,738 low-cost OHA dispensing
events). Figure 3 demonstrates the results of segmenta-
tion regression for 36-quarter intervals. In the LCPP
group post-LCPP implementation and controlling for
baseline trends, no sudden changes of the proportion of
low-cost medication use were found (p = 0.14), and a
slight decline of slope was observed (−0.01, p< 0.0001).
Similarly, in the non-LCPP group, there was also nonts(OHA) by chain 2008–2010.
Table 2 Proportion of patients using selected oral hypoglycemic agent (OHA) by chain
Ingredient MEPS Chain14 Chain11 Chain1 Chain10 Chain4 Chain2 Chain5 Chain13
Chlorpropamide * 0.2 0.04 0.01 0 0.02 0 0 0 0.03
Glimepiride * 9.1 17.1 19.4 18.8 18.0 17.8 22.4 16.5 19.9
Glipizide * 14.5 17.6 20.3 23.8 20.4 20.3 18.6 12.9 19.6
Glyburide * 10.7 4.3 5.9 3.7 4.9 4.2 2.6 3.4 4.6
Metformin * 51.0 69.1 72.8 53.3 72.8 62.4 66.2 80.0 59.9
Acarbose 0.1 0.4 0.3 0.9 0.4 0.2 0.2 0.2 0.4
Glimepiride/Pioglitazone 0.3 0.2 0.26 1.1 0.2 0.1 0.8 0.1 0.2
Glimepiride/Rosiglitazone 0.5 0.4 0.17 0.4 0.4 0.6 0.4 0.2 0.5
Glipizide/Metformin 0.1 0.6 0.56 0.9 0.5 0.8 0.6 0.2 0.7
Glyburide/Metformin 4.1 4.0 3.8 6.3 1.5 2.6 3.6 1.2 4.1
Pioglitazone 11.1 17.5 15.4 27.1 15.9 19.2 22.2 14.9 25.8
Pioglitazone/Metformin 1.8 3.3 2.5 1.1 2.6 3.0 2.4 1.6 3.6
Repaglinde 0.8 0.8 0.5 0.9 0.6 0.9 0.8 0.1 1.0
Rosiglitazone 0.5 3.0 2.3 6.8 3.1 3.0 3.4 2.3 5.6
Rosiglitazone/Metformin 0.6 1.4 1.1 2.3 1.6 1.5 1.8 1.2 2.0
Sitagliptin 4.0 10.8 9.0 12.2 9.4 12.7 12.2 8.8 14.3
Sitagliptin/Metformin 1.1 4.9 4.3 2.8 4.5 6.7 6.1 4.5 5.3
Low-cost OHA 85.3 89.0 78.5 89.0 83.2 83.4 90.0 79.0
Non-low-cost OHA 55.3 33.8 52.1 34.4 43.4 43.7 29.3 52.2
*low-cost oral antidiabetic medication.
Figure 3 Trend of proportion of patients using low-cost oral hypoglycemic agent (OHA) in chains with or without a low-cost program
from 2002 to 2010.
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however, there was a change in slope (−0.01, p< 0.0001)
over time. In the segmentation regression with two
groups, there was no difference between the groups in
prior trend (p = 0.35). After LCPP implementation, the
immediate change was not significantly different for the
LCPP and non-LCPP groups (p = 0.88), and there was no
significant difference between the LCPP and non-LCPP
groups in the change in slope (p = 0.57).
Discussion
To our knowledge, this is the first study that investigated
whether LCPPs decrease data availability of low-cost
medication dispensing events. We did not find any evi-
dence to support the concern voiced by some research-
ers that pharmacies may not be sending claims for low-
cost generic medications to PBMs. The estimated pro-
portion of patients receiving each anti-diabetic medica-
tion was comparable not only across chains, regardless
of whether they offered an LCPP, but also before and
after the time frame in which chains implemented
LCPPs. In addition, from the longitudinal data, we fur-
ther observed no significant difference in changes in the
level and slope of the proportion of low-cost medication
use after LCPP implementation between chains with and
without LCPP.
In the longitudinal data set, low-cost OHA use has
been rapidly increasing from 2002 to 2006. A slower
growing of the proportion of low-cost medication use
has been observed in chains with and without LCPP in
the beginning of 2007. Possible explanation could be an
amount of patients dispensed preferred branded antidia-
betic medications even the insurance program has
encouraged using generic OHAs. In addition, some
patients in this population might be eligible for Medicare
Part D program when it was implemented in 2006,
which we might not capture complete medication dis-
pensing information for these patients.
The proportions for anti-diabetic drugs which are not
included in the LCPPs were similar between chains
offering LCPPs and those that do not, which increases
our confidence in our estimation process. In addition,
the similarities of the proportion of patients using each
OHA between our estimates based on pharmacy claims
and estimates from the MEPS data increase support our
belief that our claims-based estimates are reasonable.
From these experiences, we did not find evidence to
support the concern that the PBMs do not capture dis-
pensing events of low-cost medications in chains with
LCPP. We speculate that because of the level of automa-
tion of the submission process in most pharmacies and
the minimal cost of transmitting these transactions that,
unless a patient pays cash and specifically requests that
the pharmacy not share the data with the patient’s payor,the pharmacy will send the claim to the patient’s PBM.
To not send in the claim, the technician or the pharma-
cist would have to change the patient’s payer to "cash",
which would require more work than submitting a claim
to the third-party when the patient has active prescrip-
tion drug coverage in their profile.Limitation
It is possible that the central Indiana population may
not be representative of other populations but the
demographics are similar to the overall US population.
We only studied OHAs in diabetic patients who have
active insurance coverage. Findings may not apply to
other medications in the LCPP or to patients without
active insurance coverage. In addition, we were not
able to directly measure the proportion of patients re-
ceiving OHAs to compare with the estimate based on
claims transactions, but we believe that our approach
of comparing the proportions for patients receiving
medications from chains with and without LCPPs are
a good proxy. Note that provider orders would not
provide a good gold standard since so many prescrip-
tions go unfilled. We might not have identified all dia-
betic patients and may have included some Type 1
diabetics, but this should not introduce any systematic
bias. Further, assignment of patients to pharmacy
chains was reasonable based on at least 3 OHA dis-
pensing events during the study period, which might
exclude information from patients who had less than
three OHA dispensing records in the INPC. However,
this assignment may provide information for a more
stable study population for each chain.Conclusion
Our findings should reassure researchers that dispensing
data for medication available through LCPPs are not se-
lectively excluded from PBM or claims datasets.
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